QS/1 launches SharpRx software

SPARTANBURG, S.C. — On the heels of its unveiling a new logo and website, pharmacy software solutions company QS/1 on Wednesday announced the launch of its newest software, SharpRx, which is aimed at making filling prescriptions and billing insurance easier for independent and small-chain pharmacies. SharpRx uses touch-screen capabilities for quick navigation and also contains extensive reporting features, according to QS/1.

The company said that pharmacists asked to test SharpRx filled prescriptions before being trained. Additionally, the system works with already existing equipment like barcode scanners and printers. It also has tool for checking eligibility, ensuring prior authorization, and PMP reporting. SharpRx features a clinical update feature that has images and imprints as well as prescriber updates and remote backup.

Onco360 gains access to latest cancer drug

LOUISVILLE, Ky. — Onco360 on Wednesday announced that it has been selected by Taiho Oncology as a limited distribution pharmacy network participant for Lonsurf (trifluridine and tipiracil). With the addition of Lonsurf, Onco360 continues to grow its broad portfolio of limited distribution oncology medications.

“This is yet another example of how our differentiated oncology pharmacy model is gaining traction and recognition in the marketplace," stated Paul Jardina, president and CEO Onco360. "Onco360 is committed to providing patients with the most comprehensive oncology pharmacy care possible, and the addition of Lonsurf provides us with an important new tool in the fight against cancer.”

On Sept. 22, 2015, the U.S. Food and Drug Administration approved Lonsurf for patients with an advanced form of colorectal cancer who are no longer responding to other therapies. In 2014, the American Cancer Society estimated that 136,830 people would be diagnosed with metastatic colorectal cancer in the United States. A subset of these patients will become candidates for treatment with Lonsurf.

Lonsurf is a combination of trifluridine, a nucleoside metabolic inhibitor, and tipiracil, a thymidine phosphorylase inhibitor, indicated for the treatment of patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy.

Aligning ‘pay-for-outcomes’ pharmacy model with reimbursement

LAS VEGAS — As the healthcare industry moves toward adopting outcomes-based reimbursement, independent pharmacy owners are faced with a stark reality — they need to invest in the ability to deliver clinical outcomes long before that ability is adequately reimbursed by an evolving payment model.

Good Neighbor Pharmacy, however, is looking to ease that burden.

The question on how to successfully transition from the fee-for-service payment model in place today to the pay-for-outcomes model of the future is “one of the most complicated questions that the industry has been wrestling with for years,” noted Dave Neu, EVP Retail Strategy at AmerisourceBergen and President of Good Neighbor Pharmacy. “It’s interesting that before medication therapy management, we had reimbursement for cognitive services. We had in there a bit of clinical consulting, and it has always been about who’s going to pay for it?” he said. “And the other piece — without a centralized patient record, what value is there?”

That’s all starting to change now, slowly but surely, Neu said. “One of the things that’s happened recently with the change in health care and the Star measures, is that there is now a difference in technology to capture this information,” he said. “It’s not perfect, but the payers and the PBMs have gotten smart, and they have put incentives and disincentives in place,” he said. If you don’t show specific changes or outcomes, the reimbursement for that work may be cut or, even worse, eliminated altogether.

Eventually there will be a balance, a kind of payment for services and reimbursement for outcomes management that will morph over time, Neu suggested. “But I think we are moving forward now in a way that’s much different than the last 10 or 15 years,” he said. “And there really wasn’t a financial incentive or disincentive there [before], so that’s really started to change.”

Star ratings are taking on a greater degree of importance, noted Tripp Logan, Senior Performance Consultant at MedHere Today, during a continuing education session on “The Evolution of Star Ratings,” at Good Neighbor Pharmacy’s ThoughtSpot 2015. “Studies have been done to show that if a family member or Medicare beneficiary are looking for a Medicare Part D plan, [the Star rating] is a big deal,” he said. “On the flip side, if you have a low-performing icon on the plan finder, for Medicare Part D plans that have had three years in a row of poor performance, this is a deterrent.” The Centers for Medicare and Medicaid Services is attempting to weed out poor performers, Logan said. And that means those plans with Star measures will look for partners who can help them move the outcomes needle toward better performance.

Pharmacists can help with many of the known problems in the current healthcare system, noted Anne Burns, VP Professional Affairs of the American Pharmacists Association during a CE session titled “National Initiatives to Advance Pharmacist’s Patient Care Services.” “When pharmacists are involved, access is increased, quality is improved and costs are reduced,” she said. Access increases by tapping a health profession that’s ready and willing to help address the primary care provider shortage; quality is improved as more seniors turn to prescription medications to help manage their chronic conditions; and costs are better managed as pharmacists play a greater role in helping to manage those medications.

One key strategy to improving Star ratings is collaborating with local physician groups on patient care, as outlined by Marc Sweeney, CEO Profero Team and dean and professor of Cedarville University School of Pharmacy during his ThoughtSpot CE presentation titled, “Improvement of Patient Outcomes Through Physician-Pharmacist Collaboration.”

“My general tips for beginning these types of practices is to start with one service and expand,” Sweeney said. “Do whatever is really easy to get off the ground [like hypertension],” he said. “The number of patients who have hypertension, the medication management of it, you can assess their blood pressure and you can make a dose adjustment on their hypertensive med relatively quickly.”

According to Teresa Ash, Manager of The Medication Management Clinics at St. Rita’s at Mercy Health in Lima, Ohio, high blood pressure costs the U.S. healthcare system as much as $46 billion each year. In her CE presentation titled, “Blood Pressure Management Trying to Hit a Moving Target,” Ash noted that better controlled blood pressure ratings could result in a 35% to 40% reduction in risk of stroke, and a greater than 50% reduction in risk of heart failure.

Other opportunities Good Neighbor Pharmacy members have in linking solid outcomes to their respective pharmacy practices include incorporating a long-term care facilities service into the practice as a consultant pharmacist. Charles Mosler, professor of pharmacy practice for the University of Findlay College of Pharmacy, who moderated a continuing education course titled “The Consultant Pharmacist in Medication Regiment Review in Long-Term Care Facilities” at ThoughtSpot 2015, identified five key resources for pharmacists interested in LTC.

“If you want to get more involved with consultant pharmacy or help train new consultant pharmacists, these are the five resources that I’d really push people to [review],” he said, including the website at the Centers for Medicare and Medicaid, the Nursing Facility Survey and Regulations on www.ascp.com and TR Clark’s “Introduction to the medication regimen review,” which comes in three parts.

RELATED NEWS

The Food and Drug Administration has approved a generic of Hoffman-La Roche’s Tamiflu (oseltamivir phosphate) capsules from Lupin. The company’s generic will be available in 30-, 45- and 75-mg dosage strengths.
The product is inficated to treat acute, uncomplicated influenza A and B in patients 2 weeks of age and older, as well as to prevent influenza A and B in patients 1 year old and older. The drug had U.S. sales of roughly $467.8 million for the 12 months ended October 2017, according to IQVIA data.

Behavioral health pharmacy and telepsychiatry company Genoa, a QoL Healthcare Company, has reached a big number with its remote psychiatry offering. The Tukwila, Wash.-based company announced Tuesday that it had facilitated more than 100,000 telepsych consultations on its video conferencing platform.
Genoa attributes the milestone to its recent buildup of its telepsychiatry operations, which grew to include 35 in 2017 from 20 at the start of the year, and included 250 providers. In 2017, the company grew to serve more than 2,500 patients per week.

This year's flu continues to be Texas big, according to the Walgreens Flu Index released Wednesday, as the top 10 communities experiencing the greatest amount of flu incidence were all located in the Lone Star State for the week ended Jan. 6.
Iowa, Idaho and Arkansas rank behind Texas in terms of flu activity. And Montana, Idaho and Iowa ranked highest among states experiencing flu activity gains.

Amneal Biosciences has launched its generic of Otsuka’s Busulfex (busulfan injection, 6 mg/ml). The product is indicated to treat chronic myelogenous leukemia.
Amneal said that its generic is available in cartons of eight single-dose vials, each of which contains 60 mg of the drug in a 10-ml clear sterile solution. The product is made without natural rubber, latex, gluten or preservatives, Amneal said.
The drug had U.S. sales of roughly $80 million for the 12 months ended October 2017, according to data from IQVIA.

Amneal Pharmaceuticals has launched sevelamer carbonate tablets, 800 mg, in 270-count bottles. This generic from the Bridgewater, N.J.-based company is an AB-rated therapeutic equivalent to Renvela.
Amneal also launched five other products in addition to sevelamer carbonate:

Forgotten Password

Registration complete

REGISTER

USERNAME *

Spaces are allowed; punctuation is not allowed except for periods, hyphens, and underscores.

E-MAIL ADDRESS *

A valid e-mail address. All e-mails from the system will be sent to this address. The e-mail address is not made public and will only be used if you wish to receive a new password or wish to receive certain news or notifications by e-mail.

Password *

Confirm Password *

Please choose a password for your account; it must be 8 - 30 characters. .

First Name *

Last Name *

Company Name *

Job Title *

ZIP *

Are you a *

Retailer or Healthcare professional

Non-Retailer

How many stores do you operate?: *

Which best describes the business/industry you work in?: *

Which best describes your job title?: *

Please select the newsletters you would like to subscribe to

DSN A.M.
Daily news stories covering the retail drug industry

Breaking News
First-to-the-market with developing stories in the industry